630 Fifth Avenue
United States - Map
Myrexis, Inc., a biopharmaceutical company, focuses on identifying, evaluating, and acquiring commercial-stage biopharmaceutical assets. The company intends to acquire one or more commercial-stage biopharmaceutical assets. As of February 2012, it suspended development activities of all its preclinical and clinical programs in oncology and autoimmune diseases, and continues to pursue business development opportunities for each of its programs. The company was formerly known as Myriad Pharmaceuticals, Inc. and changed its name to Myrexis, Inc. in July 2010. Myrexis, Inc. is headquartered in New York, New York.
|Mr. Jonathan M. Couchman CFA,
Chairman, Chief Exec. Officer, Pres, Chief Financial Officer and Principal Accounting Officer
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|